March 3 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O:
AMNEAL’S BLA SUBMISSIONS FOR TWO DENOSUMAB BIOSIMILARS ACCEPTED FOR REVIEW BY U.S. FDA
AMNEAL PHARMACEUTICALS INC - FDA TARGET ACTION DATE FOR DENOSUMAB BIOSIMILARS IN Q4 2025
AMNEAL PHARMACEUTICALS INC - TO EXPAND TO SIX BIOSIMILARS BY 2027
AMNEAL PHARMA: THREE MORE BIOSIMILARS IN DEVELOPMENT
Source text: ID:nBw2Kb0ZCa
Further company coverage: AMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.